Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel, Cisplatin, and Camrelizumab in Metastatic TNBC
NCT04537286Phase 2Completed
- Sponsor
- Fudan University
- Start
- Aug 2020
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Aug 2020; status: completed.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04537286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537286.